Spitfire List Web site and blog of anti-fascist researcher and radio personality Dave Emory.

FTR #‘s 1135, Lyme Disease and Biological Warfare, Part 1

” . . . . if Willy’s claim was true, a crime against human­i­ty had been com­mit­ted by the U.S. gov­ern­ment, and then cov­ered up. . . ” Bit­ten, p. 103.

A recent book about Lyme Dis­ease sets forth cred­i­ble infor­ma­tion that the dis­ease is an out­growth of U.S. bio­log­i­cal war­fare research.

Bit­ten, The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons chron­i­cles the career of Willy Burgdor­fer, a Swiss-born expert on tick and flea-borne dis­eases who spent most of his career research­ing those areas as a U.S. bio­log­i­cal war­fare sci­en­tist.

Author Kris New­by presents sub­stan­tive evi­dence that the dis­ease stems from BW research done by Burgdor­fer and asso­ciates. (Burgdor­fer was the sci­en­tist who “dis­cov­ered” the organ­ism that caus­es Lyme Dis­ease.)

In past dis­cus­sion of Lyme Dis­ease, we have explored the incor­po­ra­tion of Nazi sci­en­tists via Oper­a­tion Paper­clip into the Amer­i­can bio­log­i­cal war­fare pro­gram and pos­si­ble links between their work and the spread of the dis­ease in Con­necti­cut, across Long Island Sound from Plum Island.

(FTR #‘s 480 and 585 high­light dis­cus­sion about Lyme Dis­ease and bio­log­i­cal war­fare.)

Burgdor­fer­’s entree into the Amer­i­can bio­log­i­cal war­fare pro­gram result­ed from his pro­fes­sion­al rela­tion­ship with long time men­tor and patron Rudolf Geigy. Geigy belonged to a fam­i­ly whose busi­ness, J.R. Geigy AG, was a Swiss chem­i­cal firm mar­ket­ing dyes and insec­ti­cides.

Sig­nif­i­cant­ly, J.R. Geigy, Ciba and San­doz com­prised a Swiss chem­i­cal car­tel formed in the after­math of World War I to com­pete with the I.G. Far­ben car­tel.

(Today, the three com­pa­nies have coa­lesced as the Swiss phar­ma­ceu­ti­cal giant Novar­tis.)

Even­tu­al­ly, the Swiss con­sor­tium was absorbed into, and became a key com­po­nent of, the I.G. Far­ben car­tel. They read­i­ly col­lab­o­rat­ed with the Third Reich:

1.–” . . . . The chap­ters on Switzer­land’s chem­i­cal indus­try are the most embar­rass­ing sec­tion of the com­mis­sion’s report. It is now clear that the direc­tors of Swiss com­pa­nies in Basel were very well aware what was going on at the time in Ger­many and had knowl­edge of the coerced employ­ment of forced labor­ers in their branch plants in Ger­many as well as of the fact that forced labor­ers died as a result of the con­di­tions in which they were held. . . .”
2.–” . . . . sev­er­al lead­ing Swiss chem­i­cal firms — includ­ing JR Geigy, Ciba, San­doz and Hoff­mann-La Roche — put their own inter­ests ahead of human­i­tar­i­an con­cerns in their deal­ing with the Nazis. . . .”
3.–” . . . .The ICE [Inde­pen­dent Com­mis­sion of Experts] con­clud­ed that the chem­i­cal firms’ boss­es in Switzer­land ‘pos­sessed a high lev­el of detailed knowl­edge about the polit­i­cal and eco­nom­ic sit­u­a­tion in Nazi Ger­many... [and] incor­po­rat­ed their knowl­edge... into their eco­nom­ic plan­ning and used it as a basis for deci­sion-mak­ing’ . . . .”
4.–” . . . . ‘Geigy main­tained par­tic­u­lar­ly good rela­tions with Claus Unge­wit­ter, the Reich com­mis­sion­er for chem­i­cals.’ . . .”
5.–” . . . . Dur­ing the war, it [Geigy] pro­duced insec­ti­cides and, most notably, the icon­ic ‘polar red’ dye that col­ored the back­ground of Nazi swasti­ka flags. . . .”

All three Swiss firms [Geigy, San­doz and Ciba] were indict­ed in the Unit­ed States in 1942 because of their col­lab­o­ra­tion with I.G. Far­ben and the Third Reich.

1.–” . . . . Those indict­ed includ­ed duPont; Allied Chem­i­cal and Dye; and Amer­i­can Cyanamid; also Far­ben affil­i­ates the Amer­i­can Ciba, San­doz and Geigy. . . .”
2.–” . . . . A long list of oth­er co-con­spir­a­tors includ­ed the Swiss Ciba, San­doz and Geigy com­pa­nies with Cincin­nati Chem­i­cal works, their joint­ly owned Amer­i­can con­cern . . . .”
3.–” . . . . When Sec­re­tary of War Stim­son and Attor­ney Gen­er­al Bid­dle agreed to post­pone the tri­al until it would not inter­fere with war pro­duc­tion, one Jus­tice Depart­ment offi­cial was quot­ed as say­ing sourly, ‘First they hurt the war effort by their restric­tive prac­tices, and then if caught they use the war effort as an excuse to avoid pros­e­cu­tion.’ . . .”

Use­ful back­ground research with which to flesh out under­stand­ing of the tit­il­lat­ing infor­ma­tion pre­sent­ed by Ms. New­by con­cern­ing Geigy and his activ­i­ties can be obtained by read­ing some of the many books avail­able for down­load on this web­site.

Numer­ous pro­grams present research on the top­ic, includ­ing FTR #511.

A key foun­da­tion­al ele­ment for the dis­cus­sion of Bit­ten is the Pen­tagon’s decades-long research into the genet­ic manip­u­la­tion of micro­bial pathogens.

1.–Nobel Prize win­ner Joshua Leder­berg warned of the con­se­quences for human­i­ty of this work: ” . . . .‘The large-scale deploy­ment of infec­tious agents is a poten­tial threat against the whole species: mutant forms of virus­es could well devel­op that would spread over the earth’s pop­u­la­tion for a new Black Death,’ said Leder­berg in a Wash­ing­ton Post edi­to­r­i­al on Sep­tem­ber 24, 1966. He added, ‘The future of the species is very much bound up with the con­trol of these weapons. Their use must be reg­u­lat­ed by the most thought­ful recon­sid­er­a­tion of U.S. and world pol­i­cy.’ . . .”
2.–The Pen­ta­gon was dis­mis­sive of the warn­ing: ” . . . . A month lat­er, the army’s Bio­log­i­cal Sub­com­mit­tee Muni­tions Advi­so­ry Group thumbed its nose at this ‘nation­al pro­nounce­ment made by promi­nent sci­en­tists.’ . . . The advi­so­ry group then con­tin­ued dis­cussing its plans for genet­ic manip­u­la­tion of microbes, new rick­ettsial and viral agents, and the devel­op­ment of a bal­anced pro­gram for both inca­pac­i­tat­ing and lethal agents. . . .”
3.–By 1962, the mil­i­tary’s plans for devel­op­ment of genet­i­cal­ly mod­i­fied microbes were devel­op­ing in earnest. ” . . . . Fort Detrick’s direc­tor of bio­log­i­cal research, Dr. J.R. Good­low, on Feb­ru­ary 16, 1962 . . . added, ‘Stud­ies of bac­te­r­i­al genet­ics are also in progress with the aim of trans­fer­ring genet­ic deter­mi­nants from one type of organ­ism to another.‘The goal of these exper­i­ments was to make bio­log­i­cal agents more vir­u­lent and resis­tant to antibi­otics. . . .”

The Pen­tagon’s genet­ic manip­u­la­tion of microor­gan­isms for bio­log­i­cal war­fare pur­pos­es involved the Rocky Moun­tain Lab and Willy Burgdor­fer.

1.–” . . . . Bioweapons researchers such as Willy knew that infect­ing large pop­u­la­tions would require expos­ing peo­ple to agents for which they had no nat­ur­al immu­ni­ty. And to do this, researchers would have to import and/or invent new microbes. They were, in essence, play­ing God, cre­at­ing ‘bac­te­ri­o­log­i­cal freaks or mutants,’ by using chem­i­cals, radi­a­tion, ultra­vi­o­let light, and oth­er agents, wrote mod­ern inves­tiga­tive jour­nal­ism pio­neer Jack Ander­son in a Wash­ing­ton Post col­umn on August 27, 1965. . . .”
2.–” . . . . Willy had already been con­duct­ing a tri­al-and-error style of genet­ic manip­u­la­tion in the same way that a corn farmer or a hog grow­er selec­tive­ly breeds strains that result in desired out­comes. He was grow­ing microbes inside ticks, hav­ing the ticks feed on ani­mals, and then har­vest­ing the microbes from the ani­mals that exhib­it­ed the lev­el of ill­ness the mil­i­tary had request­ed. . . .”
3.–” . . . . He was also simul­ta­ne­ous­ly mix­ing bac­te­ria and virus­es inside ticks, lever­ag­ing the virus’s innate abil­i­ty to manip­u­late bac­te­r­i­al genes in order to repro­duce, and thus accel­er­at­ing the rate of muta­tions and desir­able new bac­te­r­i­al traits. In 1966, Fort Detrick’s Bio­log­i­cal Sub­com­mit­tee Muni­tions Advi­so­ry Group put this emerg­ing research area at the top of its pri­or­i­ties, describ­ing it as ‘Research in micro­bial genet­ics con­cerned with aspects of trans­for­ma­tion, trans­duc­tion, and recom­bi­na­tion.’ . .”

 Inter­viewed by an indie film­mak­er named Tim Grey, Willy Burgdor­fer dis­cussed the devel­op­ment of Lyme Dis­ease as a bio­log­i­cal war­fare weapon. It was Burgdor­fer who “dis­cov­ered” the spiro­chete that caused Lyme Dis­ease in 1982. As we will see lat­er, it appears that more than one organ­ism is involved with Lyme Dis­ease.

1.–” . . . . Willy paused, then replied, ‘Ques­tion: Has [sic] Bor­re­lia Burgdor­feri have the poten­tial for bio­log­i­cal war­fare?’ As tears welled up in Willy’s eyes, he con­tin­ued, ‘Look­ing at the data, it already has. If the organ­ism stays with­in the sys­tem, you won’t even rec­og­nize what it is. In your lifes­pan, it can explode . . . We eval­u­at­ed. You nev­er deal with that [as a sci­en­tist]. You can sleep bet­ter.’ . . .”
2.–” . . . . Lat­er in the video, Grey cir­cled back to this top­ic and asked, ‘If there’s an emer­gence of a brand-new epi­dem­ic that has the tenets of all of those things that you put togeth­er, do you feel respon­si­ble for that?’ ‘Yeah. . . .’ ”
3.–” . . . . Grey asked him the one ques­tion, the only ques­tion, he real­ly cared about: ‘Was the pathogen that you found in the tick that Allen Steere [the Lyme out­break inves­ti­ga­tor] gave you the same pathogen or sim­i­lar, or a gen­er­a­tional muta­tion, of the one you pub­lished in the paper . . . the paper from 1952?’ ”
4.–” . . . . The left side of his mouth briefly curled up, as if he is think­ing, ‘Oh, well.’ Then anger flash­es across his face. ‘Yah,’ he said, more in Ger­man than Eng­lish. . . .”
5.–” . . . . It was a stun­ning admis­sion from one of the world’s fore­most author­i­ties on Lyme dis­ease. If it was true, it meant that Willy had left out essen­tial data from his sci­en­tif­ic arti­cles on the Lyme dis­ease out­break, and that as the dis­ease spread like a wild­fire in the North­east and Great Lakes regions of the Unit­ed States, he was part of the cov­er-up of the truth. . . It had been cre­at­ed in a mil­i­tary bioweapons lab for the spe­cif­ic pur­pose of harm­ing human beings. . . . ”

To con­clude the pro­gram, we high­light infor­ma­tion about what Willy termed “the Swiss Agent”–a rick­ettsia that was present in the vast major­i­ty of Lyme suf­fer­ers test­ed ear­ly in research into the dis­ease. Note that this ele­ment of analy­sis will be con­tin­ued in our next pro­gram.

Even­tu­al­ly, dis­cus­sion of the pos­si­ble role of Swiss Agent dropped out of dis­cus­sion. The dis­ap­pear­ance of the Swiss Agent from the sci­en­tif­ic ana­lyt­i­cal lit­er­a­ture coin­cid­ed with Willy’s tele­phone con­ver­sa­tions with bio­log­i­cal war­fare research vet­er­ans.

Key points of dis­cus­sion:

1.–” . . . . I would engage the sci­en­tif­ic part of his brain in answer­ing my two ques­tions: why the Lyme dis­cov­ery files were miss­ing from the Nation­al Archives, and why images of the organ­ism labeled ‘Swiss Agent’ were locat­ed in the archive fold­ers in the time-frame where one would expect the Lyme spiro­chete pic­tures to be. . . .”
2.–” . . . . He told me that in late 1979, he had test­ed ‘over one hun­dred ticks’ from Shel­ter Island, locat­ed about twen­ty miles from the Lyme out­break, and all but two had an uniden­ti­fied rick­ettsial species inside. It looked like Rick­ettsia mon­tana (now called Rick­ettsia mon­ta­nen­sis) under a micro­scope, a non-dis­ease-caus­ing cousin of the dead­ly Rick­ettsia rick­et­sii, but it was a dif­fer­ent species. . . .”
3.–” . . . .‘You say they’re not look­ing for it any­more?’ I asked. ‘They prob­a­bly paid peo­ple off,’ he said. ‘There are folks up there who have a way to enable that.’ . . .”
4.–” . . . . Next, I showed Willy an unla­beled image of a microbe and asked him what it was. ‘That is a Swiss Agent,’ said Willy. I asked him a series of ques­tions on this microbe and he recit­ed what seemed like well-rehearsed lines: the Swiss Agent is a Rick­ettsia mon­tana-like organ­ism found in the Euro­pean sheep tick, Ixodes Rici­nus, and it doesn’t cause dis­ease in humans. . . .”
5.–” . . . . Then I asked him why he brought sam­ples of it from Switzer­land back to his lab. He replied with the response that he often used when he seemed to know the answer but wasn’t going to divulge it: ‘Ques­tion mark.’. . .”
6.–” . . . . The real ‘smok­ing gun,’ though, was Willy’s hand­writ­ten lab notes on the patient blood tests from the dis­ease out­break in Con­necti­cut. These tests showed the proof-of-pres­ence of what I named ‘Swiss Agent USA,’ the mys­tery rick­ettsia present in most of the patients from the orig­i­nal Lyme out­break, a fact that was nev­er dis­closed in jour­nal arti­cles. It didn’t take a PhD in micro­bi­ol­o­gy to see that almost all the patient blood had react­ed strong­ly to an anti­gen test for a Euro­pean rick­ettsia that Willy had called the Swiss Agent. . . .”

Lyme Disease and Biological Warfare, Part 3: The “Swiss Agent”

“Bit­ten, The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons” chron­i­cles the career of Willy Burgdor­fer, a Swiss-born expert on tick and flea-borne dis­eases who spent most of his career research­ing those areas as a U.S. bio­log­i­cal war­fare sci­en­tist. Author Kris
New­by presents sub­stan­tive evi­dence that the dis­ease stems from BW research done by Burgdor­fer and asso­ciates. Lis­ten­ers and read­ers are emphat­i­cal­ly encour­aged to pur­chase and read her book. In this post, we high­light infor­ma­tion about what Willy termed “the Swiss Agent”–a rick­ettsia that was present in the vast major­i­ty of Lyme suf­fer­ers test­ed ear­ly in research into the dis­ease. The dis­ap­pear­ance of the Swiss Agent USA from the lit­er­a­ture on Lyme Dis­ease cor­re­spond­ed with an impor­tant con­ver­sa­tion that Willy had: ” . . . . It was in the begin­ning of 1980—two years before the first Lyme spiro­chetes were found—that the Swiss Agent USA dis­ap­peared. This about-face coin­cid­ed with a series of dis­cus­sions Willy had with old bioweapons devel­op­ers on the Rick­ettsial Com­mis­sion of the Armed Forces Epi­demi­o­log­i­cal Board, as record­ed in his per­son­al phone log. These sci­en­tists were most cer­tain­ly famil­iar with the secret his­to­ry of inca­pac­i­tat­ing rick­ettsial and viral agent test­ing, and they may have dis­cussed with Willy the pos­si­bil­i­ty of there hav­ing been an undis­closed field test in the Long Island region. . . .”

Lyme Disease and Biological Warfare, Part 2

“Bit­ten, The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons” chron­i­cles the career of Willy Burgdor­fer, a Swiss-born expert on tick and flea-borne dis­eases who spent most of his career research­ing those areas as a U.S. bio­log­i­cal war­fare sci­en­tist. Author Kris
New­by presents sub­stan­tive evi­dence that the dis­ease stems from BW research done by Burgdor­fer and asso­ciates. Lis­ten­ers and read­ers are emphat­i­cal­ly encour­aged to pur­chase and read her book. A key foun­da­tion­al ele­ment for the dis­cus­sion of “Bit­ten” is the Pen­tagon’s decades-long research into the genet­ic manip­u­la­tion of micro­bial pathogens. Nobel Prize win­ner Joshua Leder­berg warned of the con­se­quences for human­i­ty of this work: ” . . . .‘The large-scale deploy­ment of infec­tious agents is a poten­tial threat against the whole species: mutant forms of virus­es could well devel­op that would spread over the earth’s pop­u­la­tion for a new Black Death,’ said Leder­berg in a Wash­ing­ton Post edi­to­r­i­al on Sep­tem­ber 24, 1966. . . .” Dr. Leder­berg’s warn­ing went unheed­ed: ” . . . . Fort Detrick’s direc­tor of bio­log­i­cal research, Dr. J.R. Good­low, on Feb­ru­ary 16, 1962 . . . added, ‘Stud­ies of bac­te­r­i­al genet­ics are also in progress with the aim of trans­fer­ring genet­ic deter­mi­nants from one type of organ­ism to another.‘The goal of these exper­i­ments was to make bio­log­i­cal agents more vir­u­lent and resis­tant to antibi­otics. . . .” Lyme Dis­ease “dis­cov­er­er” Willy Burgdor­fer focused on genet­ic manip­u­la­tion: ” . . . . He was also simul­ta­ne­ous­ly mix­ing bac­te­ria and virus­es inside ticks, lever­ag­ing the virus’s innate abil­i­ty to manip­u­late bac­te­r­i­al genes in order to repro­duce, and thus accel­er­at­ing the rate of muta­tions and desir­able new bac­te­r­i­al traits. In 1966, Fort Detrick’s Bio­log­i­cal Sub­com­mit­tee Muni­tions Advi­so­ry Group put this emerg­ing research area at the top of its pri­or­i­ties, describ­ing it as ‘Research in micro­bial genet­ics con­cerned with aspects of trans­for­ma­tion, trans­duc­tion, and recom­bi­na­tion.’ . .”

Lyme Disease and Biological Warfare

“Bit­ten, The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons” chron­i­cles the career of Willy Burgdor­fer, a Swiss-born expert on tick and flea-borne dis­eases who spent most of his career research­ing those areas as a U.S. bio­log­i­cal war­fare sci­en­tist. Author Kris
New­by presents sub­stan­tive evi­dence that the dis­ease stems from BW research done by Burgdor­fer and asso­ciates. Lis­ten­ers and read­ers are emphat­i­cal­ly encour­aged to pur­chase and read her book. Inter­viewed by an indie film­mak­er named Tim Grey, Willy Burgdor­fer dis­cussed the devel­op­ment of Lyme Dis­ease as a bio­log­i­cal war­fare weapon. It was Burgdor­fer who “dis­cov­ered” the spiro­chete that caused Lyme Dis­ease in 1982. As we will see lat­er, it appears that more than one organ­ism is involved with Lyme Dis­ease. ” . . . . Final­ly, after three hours and four­teen min­utes, Grey asked him the one ques­tion, the only ques­tion, he real­ly cared about: ‘was the pathogen that you found in the tick that Allen Steere [the Lyme out­break inves­ti­ga­tor] gave you the same pathogen or sim­i­lar, or a gen­er­a­tional muta­tion, of the one you pub­lished in the paper . . . the paper from 1952?’ In response, Willy crossed his arms defen­sive­ly, took a deep breath, and stared into the cam­era for forty-three seconds—an eter­ni­ty. Then he looked away, down and to the right; he appeared to be work­ing through an inter­nal debate. The left side of his mouth briefly curled up, as if he is think­ing, ‘Oh, well.’ Then anger flash­es across his face. ‘Yah,’ he said, more in Ger­man than Eng­lish. . . . It was a stun­ning admis­sion from one of the world’s fore­most author­i­ties on Lyme dis­ease. . . . He seemed to be say­ing that Lyme wasn’t a nat­u­ral­ly occur­ring germ. . . .”

FTR #1134 Bio-Psy-Op Apocalypse Now, Part 9: Covid-19 Updates

As indi­cat­ed by the title of the pro­gram, this broad­cast updates var­i­ous arti­cles and book excerpts con­cern­ing Covid-19.

A Dai­ly Mail Online [UK] arti­cle sets forth two bogus papers con­tend­ing that the SARS CoV‑2 virus was genet­i­cal­ly engi­neered by the Chi­nese as a bioweapon in a lab­o­ra­to­ry and that it “escaped.” Note the cham­pi­oning of one of the papers by a for­mer head of MI6 and the author­ship of the sec­ond by The Epoch Times, the paper of the Falun Gong cult. Linked to CIA, Steve Ban­non’s anti-Chi­na milieu and the Trump admin­is­tra­tion, the orga­ni­za­tion is a fas­cist mind con­trol cult dis­cussed in numer­ous shows, includ­ing FTR #‘s 1089 and 1090. 

1.–“A for­mer MI6 chief was yes­ter­day accused by Gov­ern­ment offi­cials of ped­dling ‘fan­ci­ful claims’ that coro­n­avirus was acci­den­tal­ly cre­at­ed in a Chi­nese lab­o­ra­to­ry. British secu­ri­ty agen­cies believe Covid-19 is not a man-made virus and is ‘high­ly like­ly’ to have occurred nat­u­ral­ly and spread to humans through ani­mals. And Health Sec­re­tary Matt Han­cock has said there is ‘no evi­dence’ to back up the the­o­ry that it orig­i­nat­ed in a lab­o­ra­to­ry. But Sir Richard Dearlove, who was head of the MI6 from 1999 to 2004, cit­ed a recent report claim­ing the dis­ease was acci­den­tal­ly man­u­fac­tured by Chi­nese sci­en­tists.
2.–“ ‘I do think that this start­ed as an acci­dent,’ Sir Richard told The Dai­ly Telegraph’s ‘Plan­et Nor­mal’ pod­cast. ‘It rais­es the issue: if Chi­na ever were to admit respon­si­bil­i­ty, does it pay repa­ra­tions? I think it will make every coun­try in the world rethink how it treats its rela­tion­ship with Chi­na.’ He added: ‘Look at the sto­ries... of attempts by the [Bei­jing] lead­er­ship to lock down any debate about the ori­gins of the pan­dem­ic and the way peo­ple have been arrest­ed or silenced.’ . . . . The paper – co-authored by Pro­fes­sor Angus Dal­gleish, a renowned oncol­o­gist and vac­cine researcher who works at St George’s Hos­pi­tal, Uni­ver­si­ty of Lon­don, and Birg­er Sorensen, a Nor­we­gian virol­o­gist – con­tains none of the stark alle­ga­tions that orig­i­nal­ly stunned its review­ers.
3..–“The ini­tial paper that trig­gered wild rumours failed strin­gent tests of ver­i­fi­ca­tion and is under­stood to have been reject­ed in April by emi­nent inter­na­tion­al jour­nals such as Nature and the Jour­nal of Virol­o­gy. Bio­med­ical experts from the Fran­cis Crick Insti­tute and Impe­r­i­al Col­lege Lon­don are said to have refut­ed its con­clu­sions. Then one of the paper’s co-authors, Dr John Fredrik Moxnes, chief sci­en­tif­ic advis­er to the Nor­we­gian mil­i­tary, asked for his name to be with­drawn. This week, after numer­ous rewrites, the paper was pub­lished by the Quar­ter­ly Review of Bio­physics Dis­cov­ery. And those orig­i­nal world-shak­ing con­clu­sions have now with­ered to innu­en­do. No accu­sa­tion of Chi­nese manip­u­la­tion appears. . . .”
4.–”. . . . Back in April, a slick­ly pro­duced inves­tiga­tive doc­u­men­tary, Track­ing Down The Ori­gin Of The Wuhan Coro­n­avirus, was released online. It claimed con­clu­sive proof that the Covid-19 virus had been cre­at­ed as a bio­log­i­cal ‘weapon of mass destruc­tion’ in a Chi­nese lab. . . .”
5.–“At first sight, it seemed a shock­ing­ly con­vinc­ing piece of jour­nal­ism. On behalf of this news­pa­per, I cross-checked every claim: The experts it cit­ed and the fac­tu­al evi­dence unearthed. I also researched the back­grounds of its mak­ers. I then approached some of the world’s best inde­pen­dent sci­en­tif­ic author­i­ties to ask their opin­ion. They all agreed – this entic­ing­ly spicy sto­ry just did­n’t stand up.”
6.–“It had been pro­duced by a US based anti-Chi­nese gov­ern­ment media organ­i­sa­tion called the Epoch Times. Its ‘experts’ were vet­er­an hard-Right­ists. Most damn­ing­ly, its sci­en­tif­ic ‘facts’ were twist­ed out of shape.So much, then, for the Chi­nese-man­u­fac­tured coro­n­avirus con­spir­a­cy . . .”

Steve Ban­non is at the epi­cen­ter of the anti-Chi­na effort and–to no one’s surprise–never real­ly left the Trump White House.

When assess­ing Ban­non as a polit­i­cal ani­mal, one should nev­er for­get that among the impor­tant ide­o­log­i­cal influ­ences on him is Julius Evola, an Ital­ian fas­cist who found Mus­soli­ni too mod­er­ate and ulti­mate­ly took his cues from the Nazi SS, who were financ­ing his work by the end of World War II.

” . . . . Don­ald Trump’s light­ning-rod 2016 cam­paign boss and for­mer White House chief strate­gist who was ban­ished from the West Wing in 2017 has qui­et­ly crept back into 1600 Penn­syl­va­nia Ave., reestab­lish­ing ties to staffers, par­tic­u­lar­ly with regard to his pet issues of Chi­na and immi­gra­tion. . . . Anoth­er for­mer admin­is­tra­tion offi­cial told The Post that Ban­non nev­er real­ly left the White House after he was fired, main­tain­ing con­tacts and keep­ing up reg­u­lar chan­nels of com­mu­ni­ca­tions with offi­cials there. . . .”

In addi­tion, as dis­cussed in FTR #‘s 1111 and 1112, Ban­non is part of a net­work that includes J. Kyle Bass and Tom­my Hicks, Jr. This nexus involves asym­met­ri­cal invest­ing with regard to the Hong Kong and Chi­nese economies and the inter-agency gov­ern­men­tal net­works involved in both overt and covert anti-Chi­na poli­cies imple­ment­ed by Team Trump. As will be seen below, they also are net­work­ing with the mis-named “Sci­en­tists to Stop Covid-19.” In that regard, they are also help­ing steer pol­i­cy that con­trols devel­op­ment of treat­ment and vac­cines for Covid-19. The man­age­ment of drug and vac­cine devel­op­ment, in turn, dou­bles back to mar­ket-dri­ving invest­ment dynam­ics.

An inter­est­ing sum­ma­tion of char­ac­ter­is­tics of a “delib­er­ate” epi­dem­ic are eval­u­at­ed against the find­ing that New York City was the epi­cen­ter of the U.S. Covid-19 out­break: 

Bit­ten: The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons by Kris New­by; Harper­Collins [HC]; Copy­right 2019 by Kris New­by; ISBN 9780062896728; p. 185.

Poten­tial epi­demi­o­log­i­cal clues to a delib­er­ate epi­dem­ic:

Clue no. 1–A high­ly unusu­al event with large num­bers of casu­al­ties: Check!

Clue no. 2–Higher mor­bid­i­ty or mor­tal­i­ty than is expect­ed. Check!

Clue no. 3–Uncommon dis­ease. Check!

Clue no. 4–Point-source out­break. Check!

Clue no. 5–Multiple epi­demics. Check! (Glob­al pan­dem­ic)

                      –Z. F. Dem­bek, et al., “Dis­cern­ment Between Delib­er­ate and Nat­ur­al Infec­tious Dis­ease Out­breaks”

The pre­vail­ing view of the Covid-19 out­break con­tends that the Amer­i­can out­break spread out­ward from New York City. The strain of SARS CoV‑2 that appeared in New York came, in turn, from Europe. 

This does­n’t make sense. There were con­firmed cas­es of the virus on the West Coast that did not come from New York. A Euro­pean strain of the virus trans­mit­ted to New York City would have come in via air. In such an event, there would have been a well-doc­u­ment­ed out­break of Covid-19 among flight atten­dants, who oper­ate in close con­tact with pas­sen­gers in cramped cir­cum­stances, as well as expe­ri­enc­ing jet lag, which com­pro­mis­es the immune sys­tem.

Next, we review an aspect of the 2001 anthrax attacks. We high­light­ed the 2001 anthrax attacks in con­nec­tion with the Covid-19 out­break in New York City in FTR #1128.

We note that the Anthrax attacks appear to have oper­at­ed in over­lap­ping con­texts, includ­ing jus­ti­fi­ca­tion for the war in Iraq. 

The 2001 anthrax attacks appear to have served as a provo­ca­tion that jus­ti­fied a ten-fold increase in spend­ing for bio­log­i­cal war­fare devel­op­ment. The num­ber of BSL‑4 labs (hav­ing dual civil­ian and mil­i­tary use) increased from two in 2001, to a dozen in 2007.

This increase occurred while Don­ald Rums­feld was George W. Bush’s sec­re­tary of defense. He went to that posi­tion from being Chair­man of the Board of Direc­tors for Gilead Sci­ences, the man­u­fac­tur­er of remde­sivir.

We will delve into the pol­i­tics of the anthrax attacks in the future.

In the con­text of the above arti­cle, note that the Nation­al Insti­tutes of Health have also part­nered with CIA and the Pen­ta­gon, as under­scored by an arti­cle about a BSL‑4 lab at Boston Uni­ver­si­ty. Note that Europe and the U.S. have twelve BSL4 labs apiece. Tai­wan has two. Chi­na has one:

1.–As the arti­cle notes, as of 2007, the U.S. had “more than a dozen” BSL4 labs–China com­mis­sioned its first as of 2017. a ten­fold increase in fund­ing for BSL4 labs occurred because of the anthrax attacks of 2001. Those attacks might be seen as some­thing of a provo­ca­tion, spurring a dra­mat­ic increase in “dual use” biowar­fare research, under the cov­er of “legit­i­mate” medical/scientific research. In FTR #1128, we hypoth­e­sized about the milieu of Stephen Hat­fill and apartheid-linked inter­ests as pos­si­ble authors of a vec­tor­ing of New York City with Sars COV2: ” . . . . Before the anthrax mail­ings of 2001, the Unit­ed States had just two BSL4 labs—both with­in the razor-wire con­fines of gov­ern­ment-owned cam­pus­es. Now, thanks to a ten­fold increase in funding—from $200 mil­lion in 2001 to $2 bil­lion in 2006—more than a dozen such facil­i­ties can be found at uni­ver­si­ties and pri­vate com­pa­nies across the coun­try. . . .”
2.–The Boston Uni­ver­si­ty lab exem­pli­fies the Pen­ta­gon and CIA pres­ence in BSL‑4 facil­i­ty “dual use”: ” . . . . But some sci­en­tists say that argu­ment obscures the true pur­pose of the cur­rent biode­fense boom: to study poten­tial bio­log­i­cal weapons. ‘The uni­ver­si­ty por­trays it as an emerg­ing infec­tious dis­ease lab,’ says David Ozonoff, a Boston Uni­ver­si­ty epi­demi­ol­o­gist whose office is right across the street from the new BSL4 facil­i­ty. ‘But they are talk­ing about study­ing things like small pox and inhala­tion anthrax, which pose no pub­lic health threat oth­er than as bioweapons.’ . . . The orig­i­nal NIH man­date for the lab indi­cat­ed that many groups—including the CIA and Depart­ment of Defense—would be allowed to use the lab for their own research, the nature of which BU might have lit­tle con­trol over. . . .”

Piv­ot­ing to dis­cus­sion and review of the polit­i­cal, finan­cial and cor­po­rate con­nec­tions to the devel­op­ment of med­i­c­i­nal treat­ments for, and vac­cines to pre­vent, Covid-19, we recap details rel­e­vant to the extra­or­di­nary tim­ing of a 4/29 announce­ment of favor­able results for a tri­al of remde­sivir. That announce­ment drove equi­ties mar­kets high­er and was ben­e­fi­cial to the stock of Gilead Sci­ences.

We present a Stat News arti­cle on the inter­nal delib­er­a­tions behind the deci­sions to mod­i­fy the NIAID study. Of par­tic­u­lar sig­nif­i­cance is the DSMB delib­er­a­tion. Note the time­line of the DSMB delib­er­a­tion, com­bined with the announce­ment on 4/29 that drove the mar­kets high­er.

1.–The deci­sion was made to cut it short before the ques­tion of remdesivir’s impact on mor­tal­i­ty could be answered: ” . . . .The Nation­al Insti­tute of Aller­gy and Infec­tious Dis­eases has described to STAT in new detail how it made its fate­ful deci­sion: to start giv­ing remde­sivir to patients who had been assigned to receive a place­bo in the study, essen­tial­ly lim­it­ing researchers’ abil­i­ty to col­lect more data about whether the drug saves lives — some­thing the study, called ACTT‑1, sug­gests but does not prove. In the tri­al, 8% of the par­tic­i­pants giv­en remde­sivir died, com­pared with 11.6% of the place­bo group, a dif­fer­ence that was not sta­tis­ti­cal­ly sig­nif­i­cant. A top NIAID offi­cial said he had no regrets about the deci­sion. ‘There cer­tain­ly was una­nim­i­ty with­in the insti­tute that this was the right thing to do,’ said H. Clif­ford Lane, NIAID’s clin­i­cal direc­tor. . . .”
2.–In addi­tion, patients sched­uled to receive place­bo received remde­sivir, instead. ” . . . . Steven Nis­sen, a vet­er­an tri­al­ist and car­di­ol­o­gist at the Cleve­land Clin­ic, dis­agreed that giv­ing place­bo patients remde­sivir was the right call. ‘I believe it is in society’s best inter­est to deter­mine whether remde­sivir can reduce mor­tal­i­ty, and with the release of this infor­ma­tion doing a place­bo-con­trolled tri­al to deter­mine if there is a mor­tal­i­ty ben­e­fit will be very dif­fi­cult,’ he said. ‘The ques­tion is: Was there a route, or is there a route, to deter­mine if the drug can pre­vent death?’ The deci­sion is ‘a lost oppor­tu­ni­ty,’ he said. . . .”
3.–Steven Nis­sen was not alone in his crit­i­cism of the NIAID’s deci­sion. ” . . . .Peter Bach, the direc­tor of the Cen­ter for Health Pol­i­cy and Out­comes at Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter, agreed with Nis­sen. ‘The core under­stand­ing of clin­i­cal research par­tic­i­pa­tion and clin­i­cal research con­duct is we run the tri­al rig­or­ous­ly to pro­vide the most accu­rate infor­ma­tion about the right treat­ment,’ he said. And that answer, he argued, should ide­al­ly have deter­mined whether remde­sivir saves lives. The rea­son we have shut our whole soci­ety down, Bach said, is not to pre­vent Covid-19 patients from spend­ing a few more days in the hos­pi­tal. It is to pre­vent patients from dying. ‘Mor­tal­i­ty is the right end­point,’ he said. . . .”
4.–Not only was the admin­is­tra­tion of remde­sivir instead of place­bo pri­or­i­tized, but the NIAID study itself was atten­u­at­ed! ” . . . . But the change in the study’s main goal also changed the way the study would be ana­lyzed. Now, the NIAID decid­ed, the analy­sis would be cal­cu­lat­ed when 400 patients out of the 1,063 patients the study enrolled had recov­ered. If remde­sivir turned out to be much more effec­tive than expect­ed, ‘inter­im’ analy­ses would be con­duct­ed at a third and two-thirds that number.The job of review­ing these analy­ses would fall to a com­mit­tee of out­side experts on what is known as an inde­pen­dent data and safe­ty mon­i­tor­ing board, or DSMB. . . .”
5.–The per­for­mance of the DSMB for the remde­sivir study is note­wor­thy: ” . . . . But the DSMB for the remde­sivir study did not ever meet for an inter­im effi­ca­cy analy­sis, Lane said. All patients had been enrolled by April 20. The data for a DSMB meet­ing was cut off on April 22. The DSMB met and, on April 27, it made a rec­om­men­da­tion to the NIAID. . . .”
The DSMB meet­ing on 4/27 deter­mined the switch from place­bo to remde­sivir. Of para­mount impor­tance is the fact that this was JUST BEFORE the 4/29 announce­ment that drove the mar­kets high­er and the same day on which key Trump aide–and for­mer Gilead Sci­ences lob­by­ist Joe Gro­gan resigned! ” . . . . . That deci­sion, Lane said, led the NIAID to con­clude that patients who had been giv­en place­bo should be offered remde­sivir, some­thing that start­ed hap­pen­ing after April 28. . . .”
6.–Dr. Ethan Weiss gave an accu­rate eval­u­a­tion of the NIAID study: ” . . . . ‘We’ve squan­dered an incred­i­ble oppor­tu­ni­ty to do good sci­ence,’ [Dr. Ethan] Weiss said. ‘If we could ever go back and do some­thing all over, it would be the infra­struc­ture to actu­al­ly learn some­thing. Because we’re not learn­ing enough.’ . . . .”

The remark­able han­dling of the NIAID study, the tim­ing of the announce­ment of the alto­geth­er lim­it­ed suc­cess of the atten­u­at­ed tri­al and the rise in equi­ties as a result of the announce­ment may be best under­stood in the con­text of the role played in Trump pan­dem­ic deci­sion-mak­ing by an elite group of bil­lion­aires and scientists–including con­vict­ed felon Michael Milken (the “junk bond king”).

1.–” . . . . Call­ing them­selves ‘Sci­en­tists to Stop COVID-19,’ the col­lec­tion of top researchers, bil­lion­aires and indus­try cap­tains will act as an ‘ad hoc review board’ for the tor­rent of coro­n­avirus research, ‘weed­ing out’ flawed data before it reach­es pol­i­cy­mak­ers, the Wall Street Jour­nal report­ed on Mon­day. They are also act­ing as a go-between for phar­ma­ceu­ti­cal com­pa­nies seek­ing to build a com­mu­ni­ca­tion chan­nel with Trump admin­is­tra­tion offi­cials. The group . . . . has advised Nick Ayers, an aide to Vice Pres­i­dent Mike Pence, as well as oth­er agency heads, in the past month. Pence is head­ing up the White House coro­n­avirus task force. . . .”
2.–” . . . The brainy bunch is led by Thomas Cahill, a 33-year-old doc­tor who became a ven­ture cap­i­tal­ist . . . . Cahill’s clout comes from build­ing con­nec­tions through his invest­ment firm, New­path Part­ners, with Sil­i­con Valley’s Peter Thiel, the founder of Pay­Pal, and bil­lion­aire busi­ness­men Jim Palot­ta and Michael Milken. . . .”

Note that Peter Thiel played a dom­i­nant role in bankrolling New­path Part­ners, and the oth­er finan­cial angel who ele­vat­ed Cahill–Brian Sheth–introduced him to Tom­my Hicks, Jr., the co-chair­man of the RNC. In FTR #‘s 1111 and 1112, we looked at Hicks’ net­work­ing with Steve Ban­non asso­ciate J. Kyle Bass, as well as his role in the inter-agency net­works dri­ving the anti-Chi­na effort.

” . . . . At the helm of the effort: The 33-year-old and very-much-under-the-radar ven­ture cap­i­tal­ist Tom Cahill, who leads life sci­ences-focused New­path Part­ners. Cahill com­plet­ed his M.D. and PhD at Duke Uni­ver­si­ty a mere two years ago before land­ing at blue-chip invest­ment firm Rap­tor Group through a friend. He went on to found New­path with some $125 mil­lion after impress­ing well-con­nect­ed names like ven­ture cap­i­tal­ist Peter Thiel and Vista Equi­ty Part­ners co-founder Bri­an Sheth. . . . It was through Sheth, for exam­ple, that Sci­en­tists to Stop Covid-19 con­nect­ed with the co-chair­man of the Repub­li­can Nation­al Com­mit­tee, Thomas Hicks Jr. . . .”

The fed­er­al gov­ern­men­t’s extreme focus on remde­sivir has been shaped, in large mea­sure, by the influ­ence of “Sci­en­tists to Stop COVID-19”:

1.–“Scientists to Stop Covid-19” is shep­herd­ing remde­sivir: ” . . . . Sci­en­tists to Stop COVID-19 rec­om­mends that in this phase, the U.S. Food and Drug Admin­is­tra­tion (FDA) should work to coor­di­nate with Gilead phar­ma­ceu­ti­cals to focus on expe­dit­ing the results of clin­i­cal tri­als of remde­sivir, a drug iden­ti­fied as a poten­tial treat­ment for COVID-19. The group also rec­om­mends admin­is­ter­ing dos­es of the drug to patients in an ear­ly stage of infec­tion, and notes remde­sivir will essen­tial­ly be a place­hold­er until a more effec­tive treat­ment is pro­duced.
2.–The group is doing so by atten­u­at­ing the reg­u­la­to­ry process for coro­n­avirus drugs: “Gov­ern­ment enti­ties and agen­cies appear to adhere to the rec­om­men­da­tions out­lined by the group, with the Jour­nal report­ing that the FDA and the Depart­ment of Vet­er­ans Affairs (VA) have imple­ment­ed some of the sug­ges­tions, name­ly relax­ing drug man­u­fac­tur­er reg­u­la­tions and require­ments for poten­tial coro­n­avirus treat­ment drugs. . . .”

We con­clude dis­cus­sion of the remde­sivir machi­na­tions with a piece about the tim­ing of the announce­ment of Grogan’s depar­ture.

” . . . . Gro­gan has served as the direc­tor of the White House Domes­tic Pol­i­cy Coun­cil since Feb­ru­ary 2019, over­see­ing a broad array of pol­i­cy issues includ­ing health care and reg­u­la­tion. . . . Gro­gan was one of the orig­i­nal mem­bers of the White House coro­n­avirus task force launched in late Jan­u­ary. . . . Gro­gan worked as a lob­by­ist for drug com­pa­ny Gilead Sci­ences before join­ing the Trump admin­is­tra­tion. . . .”

The depar­ture was announced in the Wall Street Jour­nal on the morn­ing of Wednes­day, April 29, the same day we got our first pub­lic reports of the NIAID clin­i­cal tri­al of remde­sivir that was pos­i­tive enough to show it short­ened the time to recov­ery and the same day the FDA grant­ed remde­sivir emer­gency use sta­tus. 

Note, again, the tim­ing of the DSM­B’s actions, as well as the influ­ence of “Sci­en­tists to Stop Covid-19.”

In FTR #1130, we not­ed that Mon­cef Slaoui–formerly in charge of prod­uct devel­op­ment for Moderna–was cho­sen to head Trump’s “Oper­a­tion Warp Speed.” He will be work­ing with Four-Star Gen­er­al Gus­tave Per­na, cho­sen by Chair­man of the Joint Chiefs of Staff Gen­er­al Mark Mil­ley.

Even after agree­ing to sell his Mod­er­na stock, Mon­cef Slaoui’s invest­ments raise alarm­ing questions–note that he is a “ven­ture cap­i­tal­ist” and a long­time for­mer exec­u­tive at Glaxo-Smithk­line:

The cir­cum­stances of his appoint­ment will per­mit him to avoid scruti­ny: ” . . . . In agree­ing to accept the posi­tion, Dr. Slaoui did not come on board as a gov­ern­ment employ­ee. Instead, he is on a con­tract, receiv­ing $1 for his ser­vice. That leaves him exempt from fed­er­al dis­clo­sure rules that would require him to list his out­side posi­tions, stock hold­ings and oth­er poten­tial con­flicts. And the con­tract posi­tion is not sub­ject to the same con­flict-of-inter­est laws and reg­u­la­tions that exec­u­tive branch employ­ees must fol­low. . . .”
He will retain a great deal of Glaxo-Smithk­line stock: ” . . . . He did not say how much his GSK shares were worth. When he left the com­pa­ny in 2017, he held about [500,000 in West­ern Print Edi­tion] 240,000 shares and share equiv­a­lents, accord­ing to the drug company’s annu­al report and an analy­sis by the exec­u­tive com­pen­sa­tion firm Equi­lar. . . .”
Fur­ther analy­sis of Slaoui’s posi­tion deep­ens con­cern about the integri­ty of the process: ” . . . . ‘This is basi­cal­ly absurd,’ said Vir­ginia Can­ter, who is chief ethics coun­sel for Cit­i­zens for Respon­si­bil­i­ty and Ethics in Wash­ing­ton. ‘It allows for no pub­lic scruti­ny of his con­flicts of inter­est.’ Ms. Can­ter also said fed­er­al law barred gov­ern­ment con­trac­tors from super­vis­ing gov­ern­ment employ­ees. . . . Ms. Can­ter, a for­mer ethics lawyer in the Oba­ma and Clin­ton admin­is­tra­tions, the Secu­ri­ties and Exchange Com­mis­sion and oth­er agen­cies, point­ed out that GSK’s vac­cine can­di­date with Sanofi could wind up com­pet­ing with oth­er man­u­fac­tur­ers vying for gov­ern­ment approval and sup­port. ‘If he retains stock in com­pa­nies that are invest­ing in the devel­op­ment of a vac­cine, and he’s involved in over­see­ing this process to select the safest vac­cine to com­bat Covid-19, regard­less of how won­der­ful a per­son he is, we can’t be con­fi­dent of the integri­ty of any process in which he is involved,’ Ms. Can­ter said.In addi­tion, his affil­i­a­tion with Medicxi could com­pli­cate mat­ters: Two of its investors are GSK and a divi­sion of John­son & John­son, which is also devel­op­ing a poten­tial vac­cine. . . .”

Next, we turn to Mod­er­na’s ani­mal tri­al for the mes­sen­ger RNA vac­cine it is devel­op­ing. There are sev­er­al con­sid­er­a­tions to be weighed in con­nec­tion with the Mod­er­na vac­cine.

1.–Again, the chair­man of Trump’s “Warp Speed” vac­cine devel­op­ment program–Moncef Slaoui–was in charge of Mod­er­na’s prod­uct devel­op­ment oper­a­tion.
2.–Moderna’s tri­al with mice was pos­i­tive with regard to gen­er­at­ing anti­body lev­els high enough to pre­vent ADE.
3.–Antibody Depen­dent Enhance­ment (ADE),  is a phe­nom­e­na where low lev­els of inef­fec­tive anti­bod­ies latch onto the virus and exac­er­bate an over­ac­tive immune response that leads to the dead­liest symp­toms likes cytokine-storms. This dan­ger was seen with SARS and attempts to cre­ate a SARS vac­cine so it’s a rea­son­able fear with SARS-CoV­‑2.
4.–The Phase III (human) tri­al is going to be start­ed in July, involv­ing 30,000 peo­ple. Alarm­ing­ly, those 30,000 peo­ple will all be receiv­ing the exact same dosage, 100 micro­grams, and that means the phase III tri­al won’t be test­ing sub-opti­mal dosages. The big Phase III tri­al won’t be test­ing for ADE in humans. 
5.–We may have a night­mare sit­u­a­tion where polit­i­cal pres­sure gives undo weight to ani­mal safe­ty results, leapfrog­ging over the neces­si­ty of test­ing for side effects. 
6.–The ani­mal tri­als have been severe­ly crit­i­cized: ” . . . . ‘This is the barest begin­ning of pre­lim­i­nary infor­ma­tion,’ said Dr. Gre­go­ry Poland, an immu­nol­o­gist and vac­cine researcher at the Mayo Clin­ic who has seen the paper, which has yet to under­go peer-review. Poland said the paper was incom­plete, dis­or­ga­nized and the num­bers of ani­mals test­ed were small. . . . Poland, who was not involved with the research, said the paper leaves out ‘impor­tant para­me­ters’ that could help sci­en­tists judge the work. . . .”
7.–We MIGHT cre­ate a vac­cine that pro­tects those who get a strong immune response while endan­ger­ing those with sub-pro­tec­tive responses–a “eugenic” vac­cine.
8.–The ani­mal tri­als have been severe­ly crit­i­cized: ” . . . . ‘This is the barest begin­ning of pre­lim­i­nary infor­ma­tion,’ said Dr. Gre­go­ry Poland, an immu­nol­o­gist and vac­cine researcher at the Mayo Clin­ic who has seen the paper, which has yet to under­go peer-review. Poland said the paper was incom­plete, dis­or­ga­nized and the num­bers of ani­mals test­ed were small. . . . Poland, who was not involved with the research, said the paper leaves out ‘impor­tant para­me­ters’ that could help sci­en­tists judge the work. . . .”
9.–The phase II clin­i­cal tri­als on humans are still under­way and won’t be com­plet­ed before Novem­ber.  Phase III is going to be get­ting under­way in July. The Human clin­i­cal tri­als are already under­way at the same time the ani­mal safe­ty tri­als have yet to be com­plet­ed.
10.–Side effects can take a while to man­i­fest.

We pro­vid­ed detailed crit­i­cal com­ments on Mod­er­na’s Phase I tri­al in FTR #1132.

We con­clude with a New York Times arti­cle sets forth a “Vac­cine Octo­ber Sur­prise” sce­nario for this fall.

” . . . . In a des­per­ate search for a boost, he could release a coro­n­avirus vac­cine that has not been shown to be safe and effec­tive as an Octo­ber sur­prise. Oct. 23, 2020, 9 a.m., with 10 days before the elec­tion, Fox New releas­es a poll show­ing Pres­i­dent Trump trail­ing Joe Biden by eight per­cent­age points. Oct. 23, 2020, 3 p.m., at a hasti­ly con­vened news con­fer­ence, Pres­i­dent Trump announces that the Food and Drug Admin­is­tra­tion has just issued an Emer­gency Use Autho­riza­tion for a coro­n­avirus vac­cine. Mr. Trump declares vic­to­ry over Covid-19, demands that all busi­ness­es reopen imme­di­ate­ly and pre­dicts a rapid eco­nom­ic recov­ery. Giv­en how this pres­i­dent has behaved, this incred­i­bly dan­ger­ous sce­nario is not far-fetched. In a des­per­ate search for a polit­i­cal boost, he could release a coro­n­avirus vac­cine before it had been thor­ough­ly test­ed and shown to be safe and effec­tive. . . .”

The Deep Politics of Lyme Disease

“Bit­ten, The Secret His­to­ry of Lyme Dis­ease and Bio­log­i­cal Weapons” chron­i­cles the career of Willy Burgdor­fer, a Swiss-born expert on tick and flea-borne dis­eases who spent most of his career research­ing those areas as a U.S. bio­log­i­cal war­fare sci­en­tist. Author Kris
New­by presents sub­stan­tive evi­dence that the dis­ease stems from BW research done by Burgdor­fer and asso­ciates. (Burgdor­fer was the sci­en­tist who “dis­cov­ered” the organ­ism that caus­es Lyme Dis­ease.) Burgdor­fer­’s entree into the Amer­i­can bio­log­i­cal war­fare pro­gram result­ed from his pro­fes­sion­al rela­tion­ship with long time men­tor and patron Rudolf Geigy. Geigy belonged to a fam­i­ly whose busi­ness, J.R. Geigy AG, was a Swiss chem­i­cal firm mar­ket­ing dyes and insec­ti­cides. ” . . . . Dur­ing the war, it [Geigy] pro­duced insec­ti­cides and, most notably, the icon­ic ‘polar red’ dye that col­ored the back­ground of Nazi swasti­ka flags. . . .” The pos­si­bil­i­ty that Geigy was an oper­a­tive of the far-flung I.G. Far­ben espi­onage appa­ra­tus is one to be seri­ous­ly con­tem­plat­ed. His role in plac­ing young sci­en­tists in orga­ni­za­tions that were part of the U.S. BW pro­gram also sug­gests a pos­si­ble role as an agent of Paper­clip. ” . . . . ‘The Swiss are above sus­pi­cion,’ said Geigy, who lat­er in his life wrote a thin­ly fic­tion­al­ized novel­la, ‘Siri, Top Secret’, that describes the spy activ­i­ties he observed dur­ing his trav­els. It’s not known if Geigy par­tic­i­pat­ed in these activ­i­ties, but he did help place young researchers in insti­tu­tions that sup­port­ed the U.S. bioweapons pro­grams. . . .”
In 2001, a Swiss com­mis­sion found deep com­plic­i­ty on the part of Geigy and its car­tel part­ners: ” . . . .The ICE [Inde­pen­dent Com­mis­sion of Experts] con­clud­ed that the chem­i­cal firms’ boss­es in Switzer­land ‘pos­sessed a high lev­el of detailed knowl­edge about the polit­i­cal and eco­nom­ic sit­u­a­tion in Nazi Ger­many... [and] incor­po­rat­ed their knowl­edge... into their eco­nom­ic plan­ning and used it as a basis for deci­sion-mak­ing’ . . . ‘Geigy main­tained par­tic­u­lar­ly good rela­tions with Claus Unge­wit­ter, the Reich com­mis­sion­er for chem­i­cals.’ . . .“All three Swiss firms [Geigy, San­doz and Ciba] were indict­ed in the Unit­ed States in 1942 because of their col­lab­o­ra­tion with I.G. Far­ben and the Third Reich. ” . . . . Those indict­ed includ­ed . . . . Far­ben affil­i­ates the Amer­i­can Ciba, San­doz and Geigy. . . A long list of oth­er co-con­spir­a­tors includ­ed the Swiss Ciba, San­doz and Geigy com­pa­nies with Cincin­nati Chem­i­cal works, their joint­ly owned Amer­i­can con­cern . . . .”

FTR #1126 Bio-Psy-Op Apocalypse Now, Part 2: The Democracy-Killing Virus

We begin a series of pro­grams high­light­ing var­i­ous aspects of the “three-dimen­sion­al chess” aspect of the Covid-19 “bio-psy-op” we feel is under­way. Actu­al­ly six or sev­en dimen­sion­al chess might be a bet­ter way of express­ing this ana­lyt­i­cal con­cept.

It is of para­mount impor­tance for listeners/readers to under­stand that the con­cep­tu­al break­down is for cog­ni­tive clar­i­ty only. The bio-psy-op” is mul­ti-dimen­sion­al in its entire­ty and must be under­stood to be a type of “fascist/totalitarian lasagna” with many lay­ers to be con­sumed.

In this pro­gram, we present ways in which the Covid-19 out­break is sub­vert­ing democ­ra­cy, both inside and out­side of the Unit­ed States.

Although he has only flirt­ed with exer­cis­ing them, to date, Trump does indeed have some emer­gency pow­ers that can be invoked to fur­ther his agen­da” ” . . . . The most notable aspect of pres­i­den­tial emer­gency action doc­u­ments might be their extreme secre­cy. It’s not uncom­mon for the gov­ern­ment to clas­si­fy its plans or activ­i­ties in the area of nation­al secu­ri­ty. . . . By con­trast, we know of no evi­dence that the exec­u­tive branch has ever con­sult­ed with Con­gress — or even informed any of its mem­bers — regard­ing the con­tents of pres­i­den­tial emer­gency action doc­u­ments. . . . That is a dan­ger­ous state of affairs. The coro­n­avirus pan­dem­ic is fast becom­ing the most seri­ous cri­sis to face this coun­try since World War II. And it is hap­pen­ing under the watch of a pres­i­dent who has claimed that Arti­cle II of the Con­sti­tu­tion gives him ‘the right to do what­ev­er I want.’ It is not far-fetched to think that we might see the deploy­ment of these doc­u­ments for the first time and that they will assert pres­i­den­tial pow­ers beyond those grant­ed by Con­gress or rec­og­nized by the courts as flow­ing from the Con­sti­tu­tion. . . .”

Next, we add that the Bio-Psy-Op Apoc­a­lypse is spawn­ing total­i­tar­i­an manifestations–not surprisingly–at the Depart­ment of Jus­tice head­ed by “ex” CIA offi­cer William Barr. ” . . . . The request raised eye­brows because of its poten­tial impli­ca­tions for habeas cor­pus — the con­sti­tu­tion­al right to appear before a judge after arrest and seek release. ‘Not only would it be a vio­la­tion of that, but it says ‘affect­ing pre-arrest,’” said Nor­man L. Reimer, exec­u­tive direc­tor of the Nation­al Asso­ci­a­tion of Crim­i­nal Defense Lawyers. ‘So that means you could be arrest­ed and nev­er brought before a judge until they decide that the emer­gency or the civ­il dis­obe­di­ence is over. I find it absolute­ly ter­ri­fy­ing. Espe­cial­ly in a time of emer­gency, we should be very care­ful about grant­i­ng new pow­ers to the gov­ern­ment.’ . . .”

It will come as no sur­prise to vet­er­an lis­ten­ers, the Pen­ta­gon has con­tin­gency plans for vary­ing degrees of gov­ern­men­tal and/or civic dis­abil­i­ty. ” . . . . But Coro­n­avirus is also new ter­ri­to­ry, where the mil­i­tary itself is vul­ner­a­ble and the dis­as­ter sce­nar­ios being con­tem­plat­ed — includ­ing the pos­si­bil­i­ty of wide­spread domes­tic vio­lence as a result of food short­ages — are forc­ing plan­ners to look at what are called ‘extra­or­di­nary cir­cum­stances’. Above-Top Secret con­tin­gency plans already exist for what the mil­i­tary is sup­posed to do if all the Con­sti­tu­tion­al suc­ces­sors are inca­pac­i­tat­ed. Stand­by orders were issued more than three weeks ago to ready these plans, not just to pro­tect Wash­ing­ton but also to pre­pare for the pos­si­bil­i­ty of some form of mar­tial law. . . .”

The mil­i­tary’s con­tin­gency plans have been par­tial­ly acti­vat­ed: ” . . . . While being hit with coro­n­avirus at rates equiv­a­lent to the civil­ian pop­u­la­tion, the U.S. mil­i­tary has acti­vat­ed its ‘defense sup­port of civ­il author­i­ties’ appa­ra­tus, estab­lish­ing liaisons in all 50 states, acti­vat­ing units and com­mand posts, and mov­ing forces to pro­vide med­ical, trans­porta­tion, logis­tics, and com­mu­ni­ca­tions sup­port in New York and Wash­ing­ton states. Lt. Gen. Lau­ra Richard­son, the com­mand of Army North (ARNORTH), has request­ed and received approval for the deploy­ment of ground units in response to the now declared nation­al emer­gency. . . .”

We note, in pass­ing, that, although not in effect at this point, dis­cus­sion of “mar­tial law” are far more than just social media fod­der, to coin a term. ” . . . . Because of so many rumors fly­ing in social media, the Pen­ta­gon estab­lished a ‘rumor con­trol’ web­site to beat down sto­ries of mil­i­tary-imposed quar­an­tines and even mar­tial law. And it said it was going to lim­it details of both the spe­cif­ic num­bers of coro­n­avirus cas­es and oper­a­tional details. . . .”

Mar­tial law dis­cus­sion has been spurred by, among oth­er things, Trump’s rumi­na­tions about what he can and will do: “. . . . Ear­li­er Sat­ur­day, Mr. Trump said that he is con­sid­er­ing declar­ing an ‘enforce­able’ quar­an­tine affect­ing some res­i­dents of the New York met­ro­pol­i­tan area, pos­si­bly includ­ing New Jer­sey and Con­necti­cut. He called the region a ‘hot spot’ of the coro­n­avirus out­break sweep­ing the coun­try. . . . Mr. Trump reit­er­at­ed in his remarks before the send off of the USNS Com­fort that he was con­sid­er­ing a quar­an­tine of the area. The Com­fort is a naval hos­pi­tal boat which is car­ry­ing over 1,000 beds and 1,200 med­ical per­son­nel to New York City. . . . Using active duty troops to enforce a quar­an­tine would require the pres­i­dent to sus­pend the Posse Comi­ta­tus Act, which for­bids the use of the armed ser­vices for law enforce­ment. . . .”

Trump has plen­ty of com­pa­ny: ” . . . . In Hun­gary, a new law has grant­ed Prime Min­is­ter Vik­tor Orban the pow­er to side­step Par­lia­ment and sus­pend exist­ing laws. Mr. Orban, who declared a state of emer­gency this month, now has the sole pow­er to end the emer­gency. Par­lia­ment, where two-thirds of the seats are con­trolled by his par­ty, approved the leg­is­la­tion on Mon­day. . . .‘The draft law is alarm­ing,’ said Daniel Kar­sai, a lawyer in Budapest who said the new leg­is­la­tion had cre­at­ed ‘a big fear’ among Hun­gar­i­ans that ‘the Orban admin­is­tra­tion will be a real dic­ta­tor­ship.’ . . .”

Orban’s Hun­gary has been joined by, among oth­ers, the long-stand­ing British democ­ra­cy: ” . . . . some of the pro­vi­sions . . . . will give the gov­ern­ment unchecked con­trol. The leg­is­la­tion gives sweep­ing pow­ers to bor­der agents and the police, which could lead to indef­i­nite deten­tion and rein­force ‘hos­tile envi­ron­ment’ poli­cies against immi­grants, crit­ics said. ‘Each clause could have had months of debate, and instead it’s all being debat­ed in a few days,’ said Adam Wag­n­er, a lawyer who advis­es a par­lia­men­tary com­mit­tee on human rights. . . . ‘These are eye-water­ing pow­ers that would have not been real­ly imag­in­able in peace­time in this coun­try before,’ said Silkie Car­lo, the direc­tor of Big Broth­er Watch, a rights group. She called the mea­sures ‘dra­con­ian.’ . . . .”

Pri­va­cy is being dra­mat­i­cal­ly cur­tailed under cov­er of com­bat­ting the virus: ” . . . . As Thomas Gaulkin of the Bul­letin of the Atom­ic Sci­en­tists not­ed ear­li­er this month, many Amer­i­cans— often fierce in their objec­tions to per­ceived gov­ern­ment over­reach into their lives—might nor­mal­ly object to dystopi­an images of fly­ing robots polic­ing lock­downs. But these, of course, are not nor­mal times. ‘If drones do begin to hov­er over U.S. streets to help con­trol this pan­dem­ic,’ Gaulkin wrote, ‘it will be yet anoth­er vis­i­ble reminder that we’ve entered a pub­lic health Twi­light Zone where Amer­i­cans have no bet­ter option than to embrace what was once only imag­in­able, and nev­er real.’ . . . ”

The alpha preda­tor of the elec­tron­ic sur­veil­lance land­scape is Peter Thiel’s Palan­tir. They have land­ed two key gov­ern­ment con­tracts in con­nec­tion with the Covid-19 out­break:” . . . . Palan­tir, the $20 bil­lion-val­ued Palo Alto tech com­pa­ny backed by Face­book-fun­der Peter Thiel, has been hand­ed a $17.3 mil­lion con­tract with one of the lead­ing health bod­ies lead­ing the charge against COVID-19. It’s the biggest con­tract hand­ed to a Sil­i­con Val­ley com­pa­ny to assist America’s COVID-19 response, accord­ing to Forbes’ review of pub­lic con­tracts, and comes as oth­er Cal­i­forn­ian giants like Apple and Google try to fig­ure out how best to help gov­ern­ments fight the dead­ly virus. . . . The mon­ey, from the fed­er­al government’s COVID-19 relief fund, is for Palan­tir Gotham licens­es, accord­ing to a con­tract record reviewed by Forbes. That tech­nol­o­gy is designed to draw in data from myr­i­ad sources and, regard­less of what form or size, turn the infor­ma­tion into a coher­ent whole. The ‘plat­form’ is cus­tomized for each client, so it meets with their mis­sion needs, accord­ing to Palan­tir. . . . Palan­tir Gotham is slight­ly dif­fer­ent to Foundry, a new­er prod­uct that’s aimed more at gen­er­al users rather than data sci­ence whizzes, with more automa­tion than Gotham. As Forbes pre­vi­ous­ly report­ed, Foundry is being used by the Cen­ters for Dis­ease Con­trol and Pre­ven­tion (CDC) to ingest infor­ma­tion from all man­ner of hos­pi­tals across Amer­i­ca to see where best to pro­vide more or less resource. . . . Palan­tir is now work­ing with at least 12 gov­ern­ments on their respons­es to coro­n­avirus, accord­ing to two sources with knowl­edge of its COVID-19 work. That includes the U.K.’s Nation­al Health Ser­vice, which is using Foundry for sim­i­lar pur­pos­es as the CDC. . . .”

Exem­pli­fy­ing the mul­ti-dimen­sion­al chess sce­nario in con­nec­tion with the “bio-psy-op” is the GOP’s plan to use the Covid-19 out­break to scape­goat Chi­na and tar the Democ­rats and Joe Biden with the same brush. Of par­tic­u­lar note in this regard is the Steve Bannon‑J. Kyle Bass-Tom­my Hicks, Jr. tri­umvi­rate dis­cussed in–among oth­er programs–FTR #‘s 1111 and 1112.

At the epi­cen­ter of the anti-Chi­na effort, Ban­non is net­worked with Bass, who is asym­met­ri­cal­ly invest­ed with regard to the Hong Kong and Chi­nese economies. Hicks, in turn, is a co-investor with Bass, co-chair­man of the RNC, and one of the prime movers of the inter­a­gency gov­ern­men­tal net­works involved in the anti-Chi­na desta­bi­liza­tion oper­a­tion. This net­worked rela­tion­ship affords investors like Bass and Hicks the ulti­mate posi­tion from which to prof­it from “insid­er” infor­ma­tion. 

The syn­the­sis of covert oper­a­tions and elec­toral pol­i­tics reminds us of the 1952 elec­tion, in which Arthur Bliss Lane occu­pied a key posi­tion in the Cru­sade For Free­dom, as well as the GOP. (We dis­cussed this in AFA #37, and uti­lized infor­ma­tion from, among oth­er sources, Blow­back by Christo­pher Simp­son.

Exem­plary, as well, of the bio-psy-op as syn­the­sis of covert oper­a­tion and polit­i­cal cru­sad­ing is the GOP’s cyn­i­cal manip­u­la­tion of emer­gency appro­pri­a­tions to achieve their long­stand­ing objec­tive of crip­pling state and local gov­ern­ments, as well as dri­ving the Postal Ser­vice into bank­rupt­cy. Pri­va­tiz­ing postal ser­vice has been a right-wing/­GOP objec­tive for a long time. ” . . . . Every­one, and I mean every­one, knows what is real­ly hap­pen­ing: McConnell is try­ing to get more mon­ey for busi­ness­es while con­tin­u­ing to short­change state and local gov­ern­ments. After all, “starve the beast” — forc­ing gov­ern­ments to cut ser­vices by depriv­ing them of resources — has been Repub­li­can strat­e­gy for decades. This is just more of the same. . . . Oh, and Trump per­son­al­ly has ruled out aid for the Postal Ser­vice. . . .”

Walkin’ the Cobra in India: Hindutva Fascism’s Triumphal Revisionism

In FTR #’s 988 and 989, we set forth the assas­si­na­tion of Mahat­ma Gand­hi by an elab­o­rate, well-doc­u­ment­ed plot by the Hin­dut­va fas­cist RSS and the asso­ci­at­ed Hin­du Mahasab­ha:The RSS was mod­eled after Euro­pean fas­cist move­ments and the Hin­du Mahasab­ha open­ly emu­lat­ed the Ger­man Nazi Par­ty under Hitler, see­ing the Fuhrer’s treat­ment of the Jews as an oper­a­tional par­a­digm for their pro­posed han­dling of Indi­a’s Mus­lims.The RSS came to pow­er with the elec­tion of Naren­dra Modi, whose regime has under­tak­en a pro­gram of active per­se­cu­tion of Mus­lims and mur­der of crit­i­cal jour­nal­ists and polit­i­cal oppo­nents. Now, the Hin­du Mahasab­ha is lead­ing a pro­gram to cel­e­brate Nathu­ram Godse, the RSS assas­sin who killed Gand­hi.Yogi Adityanath, appoint­ed by Modi to lead Uttar Pradesh, has pro­posed renam­ing the city of Meerut after Godse.

FTR #1091 The Destabilization of China, Part 2

The pro­gram begins with an excerpt of AFA #37 (from the fall of 1992), deal­ing with the desta­bi­liza­tion of the U.S.S.R. Rely­ing on arti­cles from Covert Action Infor­ma­tion Bul­letin #35, by Doug Hen­wood and Sean Ger­vasi, the pro­gram reviews both NSC 68 and what Ger­vasi terms “the full court press” strat­e­gy that was its ulti­mate ful­fill­ment.

Using polit­i­cal action focused on pro­mot­ing frac­tious nation­al­ism among tar­get­ed eth­nic­i­ties with­in the tar­get­ed nation and eco­nom­ic and diplo­mat­ic pres­sure to weak­en that coun­try, the strat­e­gy worked very well with the Sovi­et Union.

It is Mr. Emory’s con­sid­ered opin­ion that the same strat­e­gy is being applied to Chi­na. Whether that strat­e­gy will be suc­cess­ful remains to be seen.

Next, we note the role of the Nation­al Endow­ment for Democ­ra­cy (an exam­ple of Orwellian Newspeak if ever there was one) in con­tin­u­ing our exam­i­na­tion of the tur­moil in Hong Kong. NED was deeply involved in the desta­bi­liza­tion of the U.S.S.R. We exam­ined NED’s role in pro­ject­ing Nazi and fas­cist ele­ments back into Lithua­nia in AFA #37, as well as FTR #858.

In this arti­cle we note: the involve­ment of the NED with the lead­ing indi­vid­u­als and insti­tu­tions involved with the tur­moil in Hong Kong; the net­work­ing between oth­er U.S. “soft-pow­er” intel­li­gence fronts with the Hong Kong activists; U.S. “Alt-right” involve­ment with the Hong Kong unrest; the meet­ing of a U.S. diplo­mat with Hong Kong activists; the net­work­ing between top Trump admin­is­tra­tion offi­cials and the Hong Kong activists; the use of anti-Chi­nese slurs dat­ing to the fight­ing between Japan and Chi­na pri­or to, and dur­ing, World War II; the use of what–if it were used by peo­ple act­ing in the U.S.–rioting and ter­ror­ism by the crowds in Hong Kong; the vio­lence used in Hong Kong includes throw­ing gaso­line bombs at the police, set­ting fire to sub­way sta­tions, attack­ing passers-by and assault­ing counter-pro­test­ers.

FTR #1088 Fascism: 2019 World Tour, Part 3.

Exem­pli­fy­ing the land­scape and oper­a­tional par­a­digm of inter­net dri­ven fas­cism, Brazil­ian YouTube fas­cists have man­i­fest­ed “An Ecosys­tem of Hate” and the “Dic­ta­tor­ship of the ‘Like.’ ”

In India, Naren­dra Mod­i’s Hin­dut­va fas­cist regime has embraced the anti-immi­grant xeno­pho­bia cen­tral to the growth and suc­cess of many fas­cist move­ments world­wide.

Politi­cians from Mod­i’s BJP have hailed Gand­hi’s assas­sin as a “patri­ot.” (The RSS–Hindutva fas­cist par­ent orga­ni­za­tion of the BJP–was the exec­u­tive force direct­ing the mur­der of Gand­hi.)

In the U.S. Rep­re­sen­ta­tive Ro Khan­na (D‑CA) has tak­en the point in reject­ing and com­bat­ting Hin­dut­va fas­cism in this coun­try.

Look­ing ahead to our next pro­gram, the racist sym­bol Pepe the Frog has been adopt­ed by the pro­test­ers in Hong Kong.

Steve Ban­non is at the cen­ter of the anti-Chi­na move­ment, sug­gest­ing that the Pepe the Frog pres­ence in Hong Kong may not be hap­pen­stance.

Custom Search

FTR BACK STORY

Even MORE Fun With Science: Earthquake Weaponry FTR #69: Tesla technology used by U.S. and U.S.S.R. to alter the weather and cause earthquakes. Read more »